echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > NEJM: Lifetime extended by 7 months! Atiliju monoantigen first-line treatment of late NSCLC is active.

    NEJM: Lifetime extended by 7 months! Atiliju monoantigen first-line treatment of late NSCLC is active.

    • Last Update: 2020-10-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, despite many advances in the treatment of metastasis non-small cell lung cancer (NSCLC), the overall prognostication of patients is still not optimistic and new treatment options are still needed.
    , the New England Journal of Medicine (NEJM) published the results of a global Phase 3 trial of the PD-L1 inhibitor atezolizumab for first-line treatment of advanced NSCLC, which extended the survival of patients with high expression of PD-L1 by 7.1 months compared to standard platinum chemotherapy.
    Screenshot Source: New England Journal of Medicine This randomized, open-label Phase 3 clinical trial included 572 metastasis non-scaly or scaly NSCLC patients who had not previously received chemotherapy and had at least 1% of tumor cells or at least 1% of tumor-immersed cells expressing PD-L1.
    this includes 18 patients with EGFR mutations or ALK mutations who have received targeted treatment, and 18 patients who have been excluded from the main analysis group but included in the safety analysis, as new data suggest that these patients may have difficulty benefiting from immuno-checkpoint inhibitor monodyme therapy.
    all patients were randomly grouped at 1:1 to receive atilijutrobe or chemotherapy.
    In the subgroup of 205 patients with the highest expression of PD-L1 and EGFR and ALK wild type, the middle total survival benefit of the athilation group was most significant, with a 41% lower risk of death than the chemotherapy group leader of 7.1 months (20.2 months vs 13.1 months).
    two groups had a non-progressed survival period of 8.1 months and 5.0 months, respectively, and a 37% reduction in the risk of disease progressity or death in the atiliju monoantigroup.
    In the subgroup of 328 patients with high or moderate expression of PD-L1 and wild type EGFR and ALK, the median total survival of the athilation group and chemotherapy group was 18.2 months and 14.9 months, respectively, and the risk of death of the athilation group was reduced by 28%.
    two groups had a non-progressed survival period of 7.2 months and 5.5 months, respectively, and a 33 per cent reduction in the risk of disease progress or death in the atili-juju monoantigroup.
    In the 554 subgroups that expressed any PD-L1 and were EGFR and ALK wild, the medium total lifetimes of the atili-pearl monoantigen and chemotherapy groups were 17.5 months and 14.1 months, respectively, but the statistical differences were not significant.
    the total survival of the atili-pearl monoantigen and chemotherapy groups in patients with different PD-L1 expression levels.
    (Photo Source: Resources) In addition, in patients with higher blood tumor mutation load (TMB), the overall survival and progress-free survival rates of the atili-pearl monoantigen group showed a better trend.
    Among all patients who could assess safety, the proportion of adverse events occurred in the atili-pearl monoantitor group was 90.2%, the proportion of adverse events in the chemotherapy group was 94.7%;
    team noted that the safety of atilijucin in this study is consistent with previous observations in the study of atilijucin monodrug therapy.
    References . . . Roy S. Herbst, et al., (2020). Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med, DOI:10.1056/NEJMoa1917346 Retrieved October 13, 2020, from.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.